B6-huDLL3 Mouse
Product Name
B6-huDLL3 Mouse
Product ID
C001854
Strain Name
C57BL/6NCya-Dll3tm1(hDLL3)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-huDLL3 Mouse (Catalog C001854) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
DLL3
Gene Alias
SCDO1
NCBI ID
Chromosome
Chr 19 (Human)
MGI ID
Datasheet
Strain Description
The DLL3 (Delta-like canonical Notch ligand 3) gene encodes a transmembrane protein belonging to the Delta/Serrate/Lag-2 (DSL) family of ligands. Functioning within the highly conserved Notch signaling pathway, DLL3 exhibits a unique, inhibitory role, contrasting with the canonical activating function of other Notch ligands. It is believed to antagonize Notch signaling by preventing ligand-receptor interactions or by promoting receptor degradation, a mechanism critical for establishing proper cell fate decisions during development [1]. This is particularly evident in the formation of somites, where DLL3's function is essential for the rhythmic segmentation of the presomitic mesoderm [2]. While its expression is largely restricted to fetal tissues and progenitor cells in healthy adults, DLL3 is ectopically and highly expressed in a number of neuroendocrine tumors, including small cell lung cancer (SCLC), making it a promising therapeutic target. Pathogenic variants in the DLL3 gene are directly linked to Spondylocostal dysostosis type 1, a congenital disorder of vertebral segmentation [3].
The B6-huDLL3 mice are a humanized model constructed through gene editing technology, in which the mouse Dll3 endogenous extracellular domain is replaced with the human DLL3 extracellular domain. The murine signal peptide and transmembrane-cytoplasmic region are preserved. This model can be used for the study of the pathological mechanisms and treatment methods of DLL3-highly-expressed malignant tumors and Spondylocostal dysostosis type 1. It can also be applied to the development of DLL3-targeted drugs.
Reference
Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci. 2019 May;110(5):1599-1608.
Ramesh PS, Chu LF. Species-specific roles of the Notch ligands, receptors, and targets orchestrating the signaling landscape of the segmentation clock. Front Cell Dev Biol. 2024 Jan 29;11:1327227.
Umair M, Younus M, Shafiq S, Nayab A, Alfadhel M. Clinical genetics of spondylocostal dysostosis: A mini review. Front Genet. 2022 Nov 25;13:996364.
Strain Strategy
Figure 1. Gene editing strategy of B6-huDLL3 mice. The mouse Dll3 endogenous extracellular domain is replaced with the human DLL3 extracellular domain. The murine signal peptide and transmembrane-cytoplasmic region are preserved.
Application Area
Screening, development, and evaluation of DLL3-targeted drugs;
Research on the pathological mechanisms and treatment methods of Spondylocostal dysostosis type 1;
Research on the pathological mechanisms and treatment methods of DLL3-highly-expressed malignant tumors.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
